
May 13 (Reuters) - Absci Corp ABSI.O:
ABSCI ANNOUNCES FIRST PARTICIPANTS DOSED IN PHASE 1 CLINICAL TRIAL OF ABS-101, A POTENTIAL BEST-IN-CLASS ANTI-TL1A ANTIBODY FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
ABSCI CORP: INTERIM DATA ANTICIPATED IN SECOND HALF OF 2025
ABSCI CORP - ABS-101 SHOWS HIGH POTENCY AND QUARTERLY DOSING POTENTIAL